Drug Profile
Research programme: thrombin inhibitors - Astex Therapeutics
Latest Information Update: 25 Jul 2011
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
- 19 Apr 2007 Preclinical trials in Thrombosis in United Kingdom (unspecified route)